Nephritis / obrzęk

1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (Hanahan D. J. et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical

1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

BACKGROUND OF THE INVENTION Platelet-activating factor (PAF) has recently been identified as an acetyl glyceryl ether phosphorylcholine (AGEPC), i.e., 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorycholine (Hanahan D. J., et al., J. Biol. Chem. 255:5514, 1980). Even before its chemical

Chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size. FIELD OF THE

Chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The invention relates to compositions and methods of use of anti-histone antibodies or antigen-binding fragments thereof. In particular embodiments, the antibodies bind to human histones H2B, H3 or H4. The anti-histone antibodies are of use for diagnosis and/or therapy of a

Nucleic acids encoding chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size. FIELD OF THE

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size. FIELD OF THE

Methods for treating sepsis using chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size. FIELD OF THE

Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size. FIELD OF THE

Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1 SL.txt and is 71,342 bytes in size. FIELD OF THE

A1 adenosine receptor antagonists

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE INVENTION The present invention relates to compounds that are A.sub.1 adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as asthma, diabetes, cardiac disorders, degenerative disorders of the central nervous system, and disease states

Methods for treatment of nephrotic syndrome and related conditions

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE DISCLOSURE The present disclosure is directed to methods for the treatment and prevention of nephrotic syndrome and conditions related thereto, such as, but not limited to, proteinuria and edema. BACKGROUND Nephrotic syndrome (NS) is a general term that refers to the loss of protein in

Methods for treatment of nephrotic syndrome and related conditions

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

FIELD OF THE DISCLOSURE The present disclosure is directed to methods for the treatment and prevention of nephrotic syndrome and conditions related thereto, such as, but not limited to, proteinuria and edema. BACKGROUND Nephrotic syndrome (NS) is a general term that refers to the loss of protein in

Pyrazolopyridine compounds which have useful pharmaceutical utility

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły

Zaloguj się Zarejestruj się

The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof. More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and posses various pharmaceutical actions

nephritis/obrzęk

1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists

1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists

Chimeric and humanized anti-histone antibodies

Chimeric and humanized anti-histone antibodies

Nucleic acids encoding chimeric and humanized anti-histone antibodies

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

Methods for treating sepsis using chimeric and humanized anti-histone antibodies

Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies

Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies

A1 adenosine receptor antagonists

Methods for treatment of nephrotic syndrome and related conditions

Methods for treatment of nephrotic syndrome and related conditions

Pyrazolopyridine compounds which have useful pharmaceutical utility

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo